January 2025

Brii Biosciences has secured complete ownership of BRII-179, a hepatitis B immunotherapy candidate, through an $18 million acquisition from VBI Vaccines and its creditors. The acquisition gives Brii full control over intellectual property, manufacturing, and supply while eliminating future milestone […]